What is Esketamine indicated for?

Esketamine is primarily indicated for treatment-resistant depression, which is a form of major depressive disorder that has not responded adequately to traditional antidepressant therapies. Evidence from clinical studies has shown that Esketamine can provide rapid relief from depressive symptoms when used in conjunction with an oral antidepressant, making it a valuable option for patients who have not found success with other treatments.

The mechanism by which Esketamine operates differs from standard antidepressants, as it acts primarily on the N-methyl-D-aspartate (NMDA) receptor, which can result in a faster onset of action compared to conventional therapies. This is particularly crucial for individuals suffering from severe depressive symptoms who need immediate assistance.

While Esketamine's effectiveness in general anxiety disorder and bipolar disorder has been studied, its primary indication and approval focus on treatment-resistant depression, further solidifying its role in addressing significant mental health challenges.